Enterome Bioscience SA - Product Pipeline Analysis, 2018 Update
September 2018
38
About the Report
About the Report
Summary
Enterome Bioscience SA (Enterome) is a drug development company that develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome-based biomarkers and screen for microbiome-derived molecules. It also develops new diagnostic products for patient classification and forecasting treatment response. Enterome provides microbiome-derived molecules as drug candidates. The company develops drugs for treatment of microbiome-related diseases which include metabolic, inflammatory bowel diseases, and central nervous system linked diseases. Enterome is headquartered in Paris, France.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Enterome Bioscience SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Enterome Bioscience SA, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
Isochem SAS
Histalim Sarl
Da Volterra SAS
Table of Contents
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Enterome Bioscience SA Company Overview 5
Enterome Bioscience SA Company Snapshot 5
Enterome Bioscience SA Pipeline Products and Ongoing Clinical Trials Overview 5
Enterome Bioscience SA-Pipeline Analysis Overview 8
Enterome Bioscience SA-Key Facts 8
Enterome Bioscience SA-Major Products and Services 9
Enterome Bioscience SA Pipeline Products by Development Stage 10
Enterome Bioscience SA Pipeline Products Overview 12
Biomarker Panel-Liver Cirrhosis 12
Biomarker Panel-Liver Cirrhosis Product Overview 12
Biomarker Test-Non-Alcoholic Fatty Liver Disease (NAFLD) 13
Biomarker Test-Non-Alcoholic Fatty Liver Disease (NAFLD) Product Overview 13
CDx Test (IBD 210) Crohn's Disease- AIEC Carriage 14
CDx Test (IBD 210) Crohn's Disease- AIEC Carriage Product Overview 14
Diagnostic Test-Autism 15
Diagnostic Test-Autism Product Overview 15
Diagnostic Test-Depression 16
Diagnostic Test-Depression Product Overview 16
Diagnostic Test-Multiple Sclerosis 17
Diagnostic Test-Multiple Sclerosis Product Overview 17
Diagnostic Test-Parkinson's Disease 18
Diagnostic Test-Parkinson's Disease Product Overview 18
Diagnostic Test-Type 2 Diabetes 19
Diagnostic Test-Type 2 Diabetes Product Overview 19
Dx test (IBD 110) Crohn's Disease-Activity Monitoring 20
Dx test (IBD 110) Crohn's Disease-Activity Monitoring Product Overview 20
EFL Test 21
EFL Test Product Overview 21
IBD 120 Ulcerative Collitis Relapse Prediction Test 22
IBD 120 Ulcerative Collitis Relapse Prediction Test Product Overview 22
IOC520 23
IOC520 Product Overview 23
MET 220 Bariatric Surgery-Outcome Prediction Test 24
MET 220 Bariatric Surgery-Outcome Prediction Test Product Overview 24
MET 230 Stratified Nutrition Test 25
MET 230 Stratified Nutrition Test Product Overview 25
Non-invasive Monitoring Tool-Cancer 26
Non-invasive Monitoring Tool-Cancer Product Overview 26
Enterome Bioscience SA-Key Competitors 27
Enterome Bioscience SA-Key Employees 28
Enterome Bioscience SA-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Enterome Bioscience SA, Recent Developments 30
Sep 20, 2017: Enterome to Move its Research Laboratories to Genopole, France's First Biocluster 30
Jul 12, 2017: Enterome Appoints Mary Thistle to its Board of Directors 30
Jul 11, 2017: Enterome and Nestle Health Sciences launch new diagnostics company 30
Dec 09, 2016: Enterome announces management changes 31
Nov 03, 2016: Enterome Appoints Christophe Bonny as Chief Scientific Officer 32
May 19, 2016: Enterome Initiates Strategic Expansion With the Opening of US Office in Cambridge, MA 32
Sep 29, 2015: Georges Gemayel Appointed Non-executive Chairman of Enterome 33
Mar 19, 2015: Oral Presentation and Poster at the IHMC congress in Luxembourg 33
Jun 17, 2014: Enterome to participate on panel at BIO2014 entitled: Microbiome Modulators: Opportunities and Challenges to Creating a New Drug Class 33
Apr 24, 2014: Enterome to Chair Panel at Forthcoming Microbiome / Microbiota R&D and Business Collaboration Forum in London, UK 34
Appendix 35
Methodology 35
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Figure
List of Figures
Enterome Bioscience SA Pipeline Products by Equipment Type 6
Enterome Bioscience SA Pipeline Products by Development Stage 10
List of Table
List of Tables
Enterome Bioscience SA Pipeline Products and Ongoing Clinical Trials Overview 5
Enterome Bioscience SA Pipeline Products by Equipment Type 6
Enterome Bioscience SA Pipeline Products by Indication 7
Enterome Bioscience SA, Key Facts 8
Enterome Bioscience SA, Major Products and Services 9
Enterome Bioscience SA Number of Pipeline Products by Development Stage 10
Enterome Bioscience SA Pipeline Products Summary by Development Stage 11
Biomarker Panel-Liver Cirrhosis-Product Status 12
Biomarker Panel-Liver Cirrhosis-Product Description 12
Biomarker Test-Non-Alcoholic Fatty Liver Disease (NAFLD)-Product Status 13
Biomarker Test-Non-Alcoholic Fatty Liver Disease (NAFLD)-Product Description 13
CDx Test (IBD 210) Crohn's Disease- AIEC Carriage-Product Status 14
CDx Test (IBD 210) Crohn's Disease- AIEC Carriage-Product Description 14
Diagnostic Test-Autism-Product Status 15
Diagnostic Test-Autism-Product Description 15
Diagnostic Test-Depression-Product Status 16
Diagnostic Test-Depression-Product Description 16
Diagnostic Test-Multiple Sclerosis-Product Status 17
Diagnostic Test-Multiple Sclerosis-Product Description 17
Diagnostic Test-Parkinson's Disease-Product Status 18
Diagnostic Test-Parkinson's Disease-Product Description 18
Diagnostic Test-Type 2 Diabetes-Product Status 19
Diagnostic Test-Type 2 Diabetes-Product Description 19
Dx test (IBD 110) Crohn's Disease-Activity Monitoring-Product Status 20
Dx test (IBD 110) Crohn's Disease-Activity Monitoring-Product Description 20
EFL Test-Product Status 21
EFL Test-Product Description 21
IBD 120 Ulcerative Collitis Relapse Prediction Test-Product Status 22
IBD 120 Ulcerative Collitis Relapse Prediction Test-Product Description 22
IOC520-Product Status 23
IOC520-Product Description 23
MET 220 Bariatric Surgery-Outcome Prediction Test-Product Status 24
MET 220 Bariatric Surgery-Outcome Prediction Test-Product Description 24
MET 230 Stratified Nutrition Test-Product Status 25
MET 230 Stratified Nutrition Test-Product Description 25
Non-invasive Monitoring Tool-Cancer-Product Status 26
Non-invasive Monitoring Tool-Cancer-Product Description 26
Enterome Bioscience SA, Key Employees 28
Enterome Bioscience SA, Subsidiaries 29
Glossary 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.